en.Wedoany.com Report, On March 25, 2026, InhaleH₂, a precision health technology company based in Snoqualmie, Washington, USA, announced that its developed hydrogen inhalation technology has received recognition from Canada's Scientific Research and Experimental Development (SR&ED) program for its breakthrough in controlled hydrogen delivery. SR&ED is the Canadian government's primary incentive program supporting scientific and technological innovation projects. This recognition indicates that InhaleH₂'s work addresses unresolved technical challenges in hydrogen therapy.
InhaleH₂'s hydrogen therapy delivery technology solves a long-standing problem: how to safely and consistently deliver precise concentrations of hydrogen gas in real-time, adapted to human breathing. Co-founder Dr. Tyler LeBaron stated, "This is the result of over seven years of dedicated research and development. We are solving a problem that has not been solved before—how to deliver hydrogen gas in a precise, safe manner that aligns with real human breathing patterns." This hydrogen therapy delivery technology overcame scientific uncertainties such as gas dynamics and human respiratory variability through systematic experimentation.
The InhaleH₂ hydrogen therapy delivery technology platform is a precise hydrogen inhalation system that provides a consistent hydrogen fraction with each breath. It allows users to set concentration targets between 0.5% and 4.0% and includes built-in safety mechanisms to ensure concentrations remain within safe thresholds. The system is designed to replicate delivery conditions used in clinical studies, supporting more consistent application of hydrogen therapy protocols. This innovation has been filed for international patents, advancing the company's mission to support clinical research.
The SR&ED recognition places InhaleH₂ among innovative Canadian companies demonstrating genuine technological advancement, solidifying its position at the forefront of hydrogen-based therapeutic delivery systems. Founded by Alex Tarnava and Dr. Tyler LeBaron, InhaleH₂ focuses on advancing hydrogen inhalation therapy through engineering innovation, enabling more precise application of hydrogen therapy in both research and consumer settings.
